Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma (PAMM-HAD1)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03490084 |
Recruitment Status :
Recruiting
First Posted : April 6, 2018
Last Update Posted : August 28, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The study aims to compare the overall survival adjusted to quality of life of 2 groups of patients with multiple myeloma, depending on the type of care: (1) day hospitalization exclusively or (2) day hospitalization combined with hospital-at-home.
As secondary objectives, the study aims to compare the impacts of the two types of care organization on:
- the survival of patients and response to treatments according to criteria of the International Myeloma Working Group,
- psychological status of patients,
- specific toxicity related to treatment used (haematological and infectious toxicity, neurotoxicity, ...),
- health outcomes,
- the caregiver's burden,
This study is combined with a qualitative study about the incentives and the barriers, and in order to set up the patient's typology.
Condition or disease | Intervention/treatment |
---|---|
Multiple Myeloma | Other: Association of day hospitalization with hospital-at-home Other: Day hospitalization exclusively |
Multiple myeloma, a malignant blood disease with about 5000 new cases diagnosed annually in France, essentially in the elderly population, is associated with alteration of quality of life resulting from pathology and therapies.
Multiples cycles of chemotherapies are administered in a regular manner, as outpatient treatment or day hospitalization.
In this study aiming to explore the impacts on health outcomes and resources utilization of hospital-at-home for elderly patients with multiple myeloma, all patients will be treated by 4 standardized protocols of treatment including bortezomib by subcutaneous administration.
9 centers will participate to the study. The study will not change the usual practices of care of these centers:
- 6 centers organize patient care through day hospitalization combined with hospital-at-home,
- 3 other centers rely exclusively on day hospitalization.
The study will target overall the inclusion of 300 patients for the 9 centers and 70 participants (35 for each arm: 10 patients, 10 caregivers, 15 from healthcare team) for the qualitative study.
The individual follow up of each patient will last 12 months. The patient's vital status will be documented at the 24th month.
Study Type : | Observational |
Estimated Enrollment : | 300 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma |
Actual Study Start Date : | February 25, 2020 |
Estimated Primary Completion Date : | October 2023 |
Estimated Study Completion Date : | October 2023 |
Group/Cohort | Intervention/treatment |
---|---|
Association of day hospitalization with hospital-at-home
Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
|
Other: Association of day hospitalization with hospital-at-home
Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home. |
Day hospitalization exclusively
Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
|
Other: Day hospitalization exclusively
Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department. |
- Change in Quality of life using questionnaires EORTC QLQ-30 [ Time Frame: At baseline, at the 6th month and the 12th month ]Comparison of quality of life using questionnaires EORTC QLQ-30.
- Change in Quality of life using questionnaires EORTC QLQ-MY20 [ Time Frame: At baseline, at the 6th month and the 12th month ]Comparison of quality of life using questionnaires EORTC QLQ-MY20.
- Survival [ Time Frame: At the 1st day of each chemotherapy cycle (each cycle varying between 28 and 35 days) ]
All patients will be evaluated in order to collect the following data:
- death and causality with multiple myeloma, treatments;
- progression or relapse according to criteria of International Myeloma Working Group;
- survival without progression, full or partial remission.
- Multidimensional evaluation of home care [ Time Frame: At baseline, at the 6th month ]RAI-HC (Resident Assessment Instrument Home Care) will be used at home. Multidimensional evaluation involves 19 areas such as sociodemographic, environmental and clinical endpoints with psychological status, cognitive status, morbidity and medication compliance defined by validated synthetic clinical scales.
- Toxicity of treatment [ Time Frame: At baseline, at each evaluation of response to therapy, at the 6th month and the 12th month ]This evaluation will be performed for all patients with the National Cancer Institute Common Terminology Criteria for Adverse Events (CRCAE version 3.0).
- family quality of life [ Time Frame: At baseline, at the 6th month and the 12th month ]Family quality of life will be evaluated with Zarit Burden Inventory
- Total Cost [ Time Frame: At the end of study: 3 years ]The following costs will be collected: hospitalization, home care, transport, biological exams, costs of chemotherapy (bortezomib) as well as indirect costs such as paid sick leave and salary of caregiver at home.
- Fate-to-face interview with patients, caregivers and healthcare staff [ Time Frame: At baseline, at the 6th month and the 12th month ]The assessment criteria are the quality care, the continuity of care, the coordination between the care actors, the information transmission, the incentives and the barriers according to the forms of hospitalization.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 65 Years and older (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Patient > 65 years;
- Resident of the departments in Île-de-France region (75, 92, 93 and 94);
- Symptomatic multiple myeloma (relapsed or no);
- Patient planned to receive one of the following chemotherapy protocols including bortezomib (VELCADE®): VMP (Velcade, Melphalan, Prednisone), VCD (Velcade, Cyclophosphamide, Dexamethasone), VelDex (Velcade, Dexamethasone), VRD (Velcade, Revlimid, Dexamethasone);
- Ineligible for autologous hematopoietic stem-cell transplantation (ASCT);
- Covered by a health insurance;
- Patient who does not oppose to the use of his/her medical data for the purpose of clinical research.
- Adult patients under guardianship will can be enrolled in the study, a consent of tutor is needed completed by patient's consent.
Exclusion Criteria:
- Resident of the departments of 77, 78 and 91 in Île-de-France region;
- Asymptomatic myeloma;
- Life expectancy < 6 months;
- Patient does not understand French language.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03490084
Contact: Bénédicte MITTAINE-MARZAC, PharmD | +33 1 42 34 84 15 | benedicte.mittaine-marzac@aphp.fr | |
Contact: Matthieu de STAMPA, MD | +33 1 73 73 59 10 | matthieu.de-stampa@aphp.fr |
France | |
HAD | Recruiting |
Paris, Île-de-France, France, 75005 |
Study Chair: | Bénédicte MITTAINE-MARZAC, PharmD | Hospitalisation à domicile (HAD), APHP | |
Study Director: | Matthieu de STAMPA, MD | Hospitalisation à domicile (HAD), APHP |
Responsible Party: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT03490084 |
Other Study ID Numbers: |
K160917J 2017-A03219-44 ( Registry Identifier: IDRCB ) |
First Posted: | April 6, 2018 Key Record Dates |
Last Update Posted: | August 28, 2023 |
Last Verified: | August 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
multiple myeloma elderly patients health outcomes hospital-at-home |
day hospitalization quality of life medico-economic evaluation qualitative study |
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases |
Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases |